← brief for 2026-09-16 · Slowing decline

Beyond Weight Loss: Thromboinflammation as a Candidate Mechanism for the Cardiovascular Benefit of GLP-1 Receptor Agonists.

Key takeaways

The SELECT trial with 17,604 people who had heart disease but no diabetes found that semaglutide cut serious heart problems like heart attack or stroke by 20% over a few years. Because it was a large, randomized trial with hard outcomes, the result is strong evidence this drug protects both heart and kidneys.

Who did this work

Melnikov I · Borodko D · Alekseev V

Source

Article · PubMed, the drug frontier · 2026 Aug 30
https://pubmed.ncbi.nlm.nih.gov/42738873/